Head-to-head comparison of disease-modifying therapies in ATTR-CM
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Ankeet Bhatt, MD
- ESC Heart Failure 2025
Greater reductions in NT-proBNP with dapagliflozin/spironolactone combination therapy in HFmrEF/HFpEF
João Pedro Ferreira, MD, PhD
- ESC Heart Failure 2025
Greater benefit of empagliflozin in HFpEF patients with features of diastolic dysfunction
João Pedro Ferreira, MD, PhD
Atsushi Tanaka, MD, PhD
